COMPASS's two-administration COMP360 TRD topline will report a numerically superior durability curve versus single-dose, but disclosure will include a re-emergence/dropout caveat that analysts flag within two weeks of release.

COMPASS Pathways is testing a version of its psilocybin treatment where patients get two doses instead of one, hoping the effects last longer for people with treatment-resistant depression — meaning depression that hasn't improved with standard antidepressants. The results will likely show the two-dose approach works better for lasting relief, but the fine print will reveal that a notable number of patients either dropped out or saw their depression come back. Analysts — the financial experts who study this company — will notice and call it out within about two weeks of the announcement.

My reviewer instinct: re-dosing designs exist because single-dose durability underwhelmed. Sponsors lead with the win, but the caveat always surfaces in the full dataset.